ClinicalTrials.gg
CompletedNCT03852459Updated Jan 25, 2022Results posted

Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS

A Phase 2 interventional study of S-Ibuprofen and Vehicle in Pain, Acute, sponsored by Aponia Laboratories, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-25.

Sponsored by Aponia Laboratories, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2018, registered Feb 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
56th of 320
251 · median 84
Started
2018
with 33 others
Phase 2
54 of 351
6 open now
Registered
164th of 351
by date

Among the 351 studies in Acute Pain with a site in United States, this one is the 56th largest by enrollment of the 320 interventional ones that give a count, is one of 34 that started in 2018, is one of 54 in phase 2, and was the 164th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

Phase 2 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%

Read the detailed description

The purpose of this randomized, double-blind study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in reducing pain/soreness associated with delayed onset muscle soreness (DOMS).

03

Conditions studied

  • Pain, Acute

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • history of pain/soreness after exercise
  • between 18-30
  • negative drug, alcohol, pregnancy screens
  • other protocol-defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • upper extremity workout in last 3 months
  • job or hobby requiring heavy lifting
  • history of muscle disorders
  • allergy or intolerance to NSAID or study drug
  • history of recent pain medication use
  • other protocol-defined exclusion criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Active Arm

    S-Ibuprofen Topical Gel 5%

    Drug: S-Ibuprofen

  • Placebo comparator
    Placebo Arm

    Vehicle Topical Gel

    Drug: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Sum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero

    The primary efficacy outcome is the sum of the time-weighted differences from baseline in muscle pain/soreness with movement over 0-24 hours post T0 (SPIDMOVE 0-24h), that is the area under the differences from baseline pain/soreness intensity difference curve. The pain intensity differences (PIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of investigational product (IP).

    Time frame: 0-24 hours.

Secondary outcomes

  1. SPIDMOVE Over the Following Intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48 and 0-48 Hours Post-T0.

    Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline pain/soreness intensity difference curve. The PIDs with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.

    Time frame: From 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28,36-48, and 0-48 hours post-T0. Time point i included 1, 2, 3, 4, 5, 6 (pre-dose), 7, 8, 9, 10, 11, 12 (pre-dose), 16, 18 (pre-dose), 20, and 24 (pre-dose) hours after the first dose.

  2. Sum of Time Weighted Differences From Baseline in Muscle Stiffness (SSID) With Movement Over the Interval

    Sum of the time-weighted differences from baseline in muscle stiffness with movement (SSIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 0-24, 24-36, 24-48, 0-36, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline stiffness difference curve. The muscle Stiffness Intensity Differences (SIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 stiffness score with movement from the stiffness score with movement at time point Ti. Positive and higher scores indicate greater reduction in stiffness. Measured by Muscle Stiffness Numerical Rating Scale (NRS) where 0 = No Stiffness and 10 = Worst Possible Stiffness at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.

    Time frame: 0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48, and 0-48 post T0

  3. Total Relief With Movement (TOTPAR) 0-6 Hours Post Time Zero

    Total relief with movement (TOTPAR) 0-6 hours post time zero TOTPAR was calculated as the sum of pain relief at time point i (PR i) times the weight for each PR i, where i referred to each pain relief scheduled assessment time point between A and B (not including B). The higher the number the better pain relief. Categorical Relief Rating Scale: Subjects rated relief from starting pain with movement using a 5-point categorical relief scale "0=no relief," "1=a little relief," "2=some relief," "3=a lot of relief," or "4=complete relief" at 1, 2, 3, 4, 5, and 6 hours post-initial IP dose and immediately prior to a subsequent dose of IP if one occurred prior to 6 hours.

    Time frame: 0-6 hours

  4. Subject Global Assessment of Study Medication Assessed at Approximately 48 Hours Post Time Zero

    Global assessment of efficacy will be assessed at approximately 48 hours post-T0 (or upon early termination if the subject withdraws prior to the 48-hour assessment). Subject Global Assessment Using Original 5 Categories as 0=poor, 1=fair, 2=good, 3=very good, 4=excellent. In addition, the 5 categories were dichotomized into 2 categories (good/very good/excellent versus poor/fair). The proportion of good, very good, and excellent ratings were calculated for each treatment.

    Time frame: 48 hours post time zero

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAE was defined as an adverse event that was new or worsened in severity after the first dose of study drug. A treatment-related TEAE was defined as a TEAE that was at least possibly related to the administration of study drug or was missing the relationship assessment. If a TEAE was recorded on multiple occasions, only the highest severity was presented.

    Time frame: Up to Day 7

07

Results

Posted Jan 25, 2022

Participant flow

This was a Phase 2/3, single-center study conducted in USA

Participant flow — Overall Study
MilestoneActive ArmPlacebo Arm
Started126125
Completed123122
Not completed33
Withdrew: Adverse event22
Withdrew: Withdrawal by subject11

Outcome measures

PrimarySum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero

The primary efficacy outcome is the sum of the time-weighted differences from baseline in muscle pain/soreness with movement over 0-24 hours post T0 (SPIDMOVE 0-24h), that is the area under the differences from baseline pain/soreness intensity difference curve. The pain intensity differences (PIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of investigational product (IP).

Time frame:
0-24 hours.
Reported as:
Mean · score on a scale*hours
Sum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero
score on a scale*hoursActive ArmPlacebo Arm
Sum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero-33.09 ± 31.311-29.09 ± 29.763
Statistical analysis
  • Active Arm vs Placebo Arm · ANCOVA · p = 0.4272
SecondarySPIDMOVE Over the Following Intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48 and 0-48 Hours Post-T0.

Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline pain/soreness intensity difference curve. The PIDs with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.

Time frame:
From 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28,36-48, and 0-48 hours post-T0. Time point i included 1, 2, 3, 4, 5, 6 (pre-dose), 7, 8, 9, 10, 11, 12 (pre-dose), 16, 18 (pre-dose), 20, and 24 (pre-dose) hours after the first dose.
Reported as:
Mean · score on a scale*hours
SPIDMOVE Over the Following Intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48 and 0-48 Hours Post-T0.
score on a scale*hoursActive ArmPlacebo Arm
0-6 hours-4.82 ± 5.478-4.06 ± 5.807
6-12 hours-8.98 ± 8.583-7.73 ± 8.412
0-12 hours-13.80 ± 13.435-11.79 ± 13.682
12-24 hours-19.29 ± 18.868-17.30 ± 17.338
24-36 hours-26.55 ± 18.582-24.35 ± 18.807
24-48 hours-60.37 ± 38.168-54.61 ± 38.604
0-36 hours-59.64 ± 48.384-53.44 ± 46.530
36-48 hours-33.82 ± 20.293-30.26 ± 20.794
0-48 hours-93.47 ± 66.331-83.71 ± 64.201
SecondarySum of Time Weighted Differences From Baseline in Muscle Stiffness (SSID) With Movement Over the Interval

Sum of the time-weighted differences from baseline in muscle stiffness with movement (SSIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 0-24, 24-36, 24-48, 0-36, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline stiffness difference curve. The muscle Stiffness Intensity Differences (SIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 stiffness score with movement from the stiffness score with movement at time point Ti. Positive and higher scores indicate greater reduction in stiffness. Measured by Muscle Stiffness Numerical Rating Scale (NRS) where 0 = No Stiffness and 10 = Worst Possible Stiffness at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.

Time frame:
0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48, and 0-48 post T0
Reported as:
Mean · score on a scale*hours
Sum of Time Weighted Differences From Baseline in Muscle Stiffness (SSID) With Movement Over the Interval
score on a scale*hoursActive ArmPlacebo Arm
0-6 hours-3.81 ± 6.218-3.33 ± 5.957
6-12 hours-7.75 ± 9.893-6.48 ± 8.796
0-12 hours-11.55 ± 15.446-9.81 ± 14.302
12-24 hours-17.20 ± 20.476-14.91 ± 19.369
0-24 hours-28.75 ± 34.920-24.72 ± 32.365
24-36 hours-23.33 ± 21.209-19.95 ± 22.555
24-48 hours-53.58 ± 44.528-44.77 ± 44.732
0-36 hours-52.08 ± 54.840-44.68 ± 53.031
36-48 hours-30.25 ± 23.947-24.82 ± 23.171
0-48 hours-82.33 ± 76.936-69.49 ± 73.804
SecondaryTotal Relief With Movement (TOTPAR) 0-6 Hours Post Time Zero

Total relief with movement (TOTPAR) 0-6 hours post time zero TOTPAR was calculated as the sum of pain relief at time point i (PR i) times the weight for each PR i, where i referred to each pain relief scheduled assessment time point between A and B (not including B). The higher the number the better pain relief. Categorical Relief Rating Scale: Subjects rated relief from starting pain with movement using a 5-point categorical relief scale "0=no relief," "1=a little relief," "2=some relief," "3=a lot of relief," or "4=complete relief" at 1, 2, 3, 4, 5, and 6 hours post-initial IP dose and immediately prior to a subsequent dose of IP if one occurred prior to 6 hours.

Time frame:
0-6 hours
Reported as:
Mean · score on a scale*hours
Total Relief With Movement (TOTPAR) 0-6 Hours Post Time Zero
score on a scale*hoursActive ArmPlacebo Arm
Total Relief With Movement (TOTPAR) 0-6 Hours Post Time Zero4.06 ± 3.4353.61 ± 3.978
SecondarySubject Global Assessment of Study Medication Assessed at Approximately 48 Hours Post Time Zero

Global assessment of efficacy will be assessed at approximately 48 hours post-T0 (or upon early termination if the subject withdraws prior to the 48-hour assessment). Subject Global Assessment Using Original 5 Categories as 0=poor, 1=fair, 2=good, 3=very good, 4=excellent. In addition, the 5 categories were dichotomized into 2 categories (good/very good/excellent versus poor/fair). The proportion of good, very good, and excellent ratings were calculated for each treatment.

Time frame:
48 hours post time zero
Reported as:
Count of participants · Participants
Subject Global Assessment of Study Medication Assessed at Approximately 48 Hours Post Time Zero
ParticipantsActive ArmPlacebo Arm
Original Categories - Poor4450
Original Categories - Fair4847
Original Categories - Good2521
Original Categories - Very good95
Original Categories - Excellent01
Dichotomized Categories - Poor/fair9297
Dichotomized Categories - Good/very good/excellent3427
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAE was defined as an adverse event that was new or worsened in severity after the first dose of study drug. A treatment-related TEAE was defined as a TEAE that was at least possibly related to the administration of study drug or was missing the relationship assessment. If a TEAE was recorded on multiple occasions, only the highest severity was presented.

Time frame:
Up to Day 7
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
participantsActive ArmPlacebo Arm
Subjects with any TEAE125121
Subjects with any treatment-related TEAEs124120
Subjects with TEAEs leading to discontinuation22
Subjects with SAEs00
TEAE with mild in severity119115
TEAE with moderate in severity64
TEAE with Severe in severity02

Adverse events

Collected over Up to Day 7. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Arm0/126 (0%)0/126 (0%)123/126 (97.6%)
Placebo Arm0/125 (0%)0/125 (0%)117/125 (93.6%)
Most frequent other events
Most frequent other events
EventActive ArmPlacebo Arm
application site erythemaGeneral disorders123/126117/125
application site pruritusGeneral disorders62/12676/125
application site painGeneral disorders70/12613/125
skin exfoliationSkin and subcutaneous tissue disorders27/1264/125
application site indurationGeneral disorders25/12621/125
musculoskeletal stiffnessMusculoskeletal and connective tissue disorders8/1268/125

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active ArmPlacebo ArmTotal
Mean28.2 ± 10.4130.6 ± 10.3729.4 ± 10.44
Sex: Female, Male
Sex: Female, Male(Participants)Active ArmPlacebo ArmTotal
Female7368141
Male5357110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active ArmPlacebo ArmTotal
Hispanic or Latino242448
Not Hispanic or Latino102101203
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active ArmPlacebo ArmTotal
American Indian or Alaska Native033
Asian6915
Native Hawaiian or Other Pacific Islander101
Black or African American123
White102102204
More than one race000
Unknown or Not Reported16925
Region of Enrollment
Region of Enrollment(participants)Active ArmPlacebo ArmTotal
United States126125251
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Active ArmPlacebo ArmTotal
Mean24.01 ± 3.14624.55 ± 3.08224.28 ± 3.120
08

Study locations

1 site
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Apr 2019, 14 months.

Results were first posted in Jan 2022, 2 years 9 months after primary completion.

Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Feb 25, 2019
StartActual
Jan 12, 2018
Primary completionActual
Apr 4, 2019
CompletionActual
Apr 11, 2019
Results first posted
Jan 25, 2022
Last update
Jan 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03852459
Lead sponsor
Aponia Laboratories, Inc.
Responsible party
Sponsor
First posted
Feb 25, 2019
Start date
Jan 12, 2018
Primary completion
Apr 4, 2019
Completion
Apr 11, 2019
Results posted
Jan 25, 2022
Last update
Jan 25, 2022

Study contacts

Todd Bertoch, MD
principal investigator · JBR Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexibuprofen

Start the discussion